Biohaven Details Pipeline Update At JP Morgan Conference

Stock.adobe.com

Biohaven presented positive news regarding its portfolio during its presentation at the 43^rd Annual J.P. Morgan Healthcare Conference on Monday, January 13.

In a press release, the company’s CEO Vlad Coric, MD, highlighted the progress the company has made with BHV-1400, a TRAP degrader developed using Biohaven’s proprietary MoDE platform. Coric said, “While we are excited about the significant progress across our entire portfolio, the first-ever data of a TRAP degrader in humans is monumental and unparalleled. The ability to only remove aberrant proteins causing disease while leaving all other immune functioning intact will usher in a new era of precision immunology. As quickly as science can identify new disease-causing proteins, our technology can quickly advance treatments for patients. I am proud of our dedicated, passionate and gifted team's unrelenting drive to transform medical care for patients suffering from severe diseases."

Biohaven’s MoDE, or molecular degrader of extracelluar proteins, platform is designed to develop treatments to remove disease-causing proteins from the body. Using this platform, the company is in various stages of clinical trials or development of four TRAP degrader molecules developed using the platform.

Biohaven’s chief translational officer, Tova Gardin, MD, MPP, discussed the benefits of this platform in the press release, saying, “With the advancements across our degrader platform, including the highly selective TRAP molecules, Biohaven inaugurates a new age of immune-modulating treatment–one which opens the potential of treating the pathogenesis of disease with precision to restore healthy homeostasis.”

Gardin continued, “The results of BHV-1400 from the first and lowest SAD cohort highlight the speed, precision, and patient-centered innovation that drives development of each of our molecules. Lowering Gd-IgA1 by 60% within hours of dose administration, BHV-1400 realizes the precision possible with MoDE degraders: The possibility of selectively degrading the pathogenic driver of disease, leaving host immunity unperturbed. Innovation extends across the MoDE platform, with new programs launched for the treatment of Graves' Disease, peripartum cardiomyopathy, and other selective TRAP degraders advancing towards development candidate nominations to potentially treat membranous nephropathy, IgG4-mediated disease, and diabetes."

The company also highlighted updates to its oncology pipeline. This includes the launch of a Phase I trial for BHV-1530 in the first half of 2025 and the collection of interim Phase I data for BHV-1510 in 2025.

Nushmia Khokhar, M.D., Biohaven chief medical officer of oncology, discussed the oncology pipeline in the press release, saying, "These are exciting times for Biohaven's oncology pipeline as we are well-positioned to introduce differentiated, next generation ADCs to the clinic. The early Phase 1 data with BHV-1510 is promising, showing not only signs of clinical activity but also minimal toxicities related to the free payload. This affirms the advantages of our conjugation technology, which provides high ADC stability.”

Khokhar continued, “The distinct profile of the novel TopoIx payload, and its potential to synergize with checkpoint inhibitor therapy, could significantly benefit patients across various cancer types. Furthermore, our collaboration with Merus and the expanded partnership with GeneQuantum—utilizing the TopoIx payload for multiple targets—demonstrate the potential of Biohaven's upcoming innovative ADCs. This includes dual-targeting ADCs, which are exciting for their potential to address challenges like tumor heterogeneity and delivery of stable ADCs with an improved therapeutic index."

Source

1. Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy. Biohaven Ltd. January 13, 2025. https://www.prnewswire.com/news-releases/biohaven-highlights-portfolio-progress-innovation-and-anticipated-milestones-at-the-43rd-annual-jp-morgan-healthcare-conference-reports-positive-degrader-data-with-rapid-deep-and-selective-lowering-of-galactose-deficient-ig-302349336.html